Inactive Instrument

Other languages Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

28/05	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
28/05	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	29/05
Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	28/05
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	28/05
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	28/05
CoStar Group has room for expansion	21/05
Transcript : Outlook Therapeutics, Inc., Q2 2024 Earnings Call, May 16, 2024	16/05
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	16/05
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	16/05
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	13/05
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	13/05
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	09/05
Outlook Therapeutics® to Present at the Retina World Congress 2024	02/05
Outlook Therapeutics, Inc. Announces Change in Headquarters Address	01/05
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	16/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC	15/04
Corporate Presentation: March 2024	29/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oncobiologics Inc Nasdaq

Equities

US68235M2044

Other languages

Filters